Technology
Health
Biotechnology

Eiger BioPharmaceuticals

$10.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.49 (5.02%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell EIGR and other stocks, options, ETFs, and crypto commission-free!

About EIGR

Eiger BioPharmaceuticals, Inc. Common Stock, also called Eiger BioPharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.

Employees
18
Headquarters
Palo Alto, California
Founded
2008
Market Cap
250.82M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
120.34K
High Today
$10.27
Low Today
$9.70
Open Price
$9.85
Volume
104.33K
52 Week High
$15.33
52 Week Low
$8.40

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2016 IPO
US

EIGR Earnings

-$1.20
-$1.05
-$0.89
-$0.74
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.74 per share
Actual
-$0.75 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.